ClinicalTrials.gg
CompletedNCT05404529Updated May 30, 2023

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

A Phase 1 interventional study of Tavapadon in Hepatic Impairment, sponsored by Cerevel Therapeutics, LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary purpose of the study is to assess the effect of hepatic impairment on the PK of tavapadon following administration of a single oral dose in participants with mild and moderate hepatic impairment relative to age, body weight, and sex-matched participants with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Healthy Volunteer
  • Mild Hepatic Impairment
  • Moderate Hepatic Impairment
03

In context

Lead sponsor

Cerevel Therapeutics, LLC is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 1 (5%) have results posted.

First submitted before Cerevel Therapeutics, LLC became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. of ≥17.5 to 42.0 0 kilograms per meter square (kg/m\^2), inclusive, and a total body weight >50 kilograms (kg) [110 pounds (lbs)].
  2. Must meet the criteria for Class A or B of the modified classification.
  3. Stable hepatic disease defined as no change in disease status in the last 28 days prior to the screening visit.
  4. Previous alcohol abuse is permitted provided that the participant is willing and able to follow lifestyle guidelines and has a negative breath alcohol test at Screening and Check-in (Day -1).

Key Exclusion Criteria:

  1. Receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine or booster within 7 days of planned dosing.
  2. Have recently been diagnosed with symptomatic Coronavirus Disease 2019 (COVID-19) or test positive for COVID-19 within 30 days prior to signing the form (ICF).
  3. Taking any prohibited medication prior to randomization or likely to require prohibited concomitant therapy.
  4. Has received study drug in a clinical trial of Tavapadon within 12 months of signing the ICF.
  5. Acute hepatitis.
  6. Grade ≥2 hepatic encephalopathy.
  7. Participants who have received an organ transplant or are currently waiting for an organ transplant and are listed on the national transplant list.
  8. Primary biliary cholangitis or primary sclerosing cholangitis.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Function

    Participants will receive a single dose of tavapadon, 0.5 milligrams (mg) or 0.25 mg tablet based on tolerability, on Day 1.

    Drug: Tavapadon

  • Experimental
    Mild Hepatic Function

    Participants will receive a single dose of tavapadon, 0.5 mg or 0.25 mg tablet based on tolerability, on Day 1.

    Drug: Tavapadon

  • Experimental
    Normal Hepatic Function

    Participants will receive a single dose of tavapadon, 0.5 mg or 0.25 mg tablet based on tolerability, on Day 1.

    Drug: Tavapadon

Interventions

  • Oral tablets

    Also known as: CVL-751

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Tavapadon

    Time frame: pre-dose and at multiple timepoints post-dose up to Day 7

  2. Area Under the Plasma Concentration-time Curve from Time Zero to t (AUC0-t) of Tavapadon

    Time frame: pre-dose and at multiple timepoints post-dose up to Day 7

  3. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Tavapadon

    Time frame: pre-dose and at multiple timepoints post-dose up to Day 7

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs) and AEs by Severity

    Time frame: Day 1 up to Follow-up (Day 15)

  2. Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECG) Values

    Time frame: Day 1 up to Follow-up (Day 15)

  3. Number of Participants with Clinically Significant Abnormalities in Vital Sign Values

    Time frame: Day 1 up to Follow-up (Day 15)

  4. Number of Participants with Clinically Significant Abnormalities in Laboratory Values

    Time frame: Day 1 up to Follow-up (Day 15)

  5. Number of Participants with Clinically Significant Abnormalities in Physical and Neurological Examination Results

    Time frame: Day 1 up to Follow-up (Day 15)

  6. Number of Participants with Change in Columbia Suicide Severity Rating Scale (C-SSRS) Score

    Time frame: Day 1 up to Follow-up (Day 15)

07

Study locations

3 sites
  • Miami, Florida
    Miami, Florida 33014, United States
  • Orlando, Florida
    Orlando, Florida 32809, United States
  • San Antonio, Texas
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jan 2023, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 3, 2022
StartActual
Apr 29, 2022
Primary completionActual
Jan 24, 2023
CompletionActual
Jan 24, 2023
Last update
May 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05404529
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Apr 29, 2022
Primary completion
Jan 24, 2023
Completion
Jan 24, 2023
Last update
May 30, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion